Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.61 |
| ▸ | CA1 | P00915 | 15/20 | 0.61 |
| ▸ | CA9 | Q16790 | 14/20 | 0.61 |
| ▸ | CA12 | O43570 | 11/20 | 0.61 |
| ▸ | CA4 | P22748 | 4/20 | 0.57 |
| ▸ | CA5A | P35218 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 3/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.57 |
| ▸ | CA6 | P23280 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414315 | 0.81 | CA2 (0.59) | CA2CA1CA9CA12CA4 | |
| SCHEMBL12903573 | 0.81 | CA2 (0.59) | CA2CA1CA9CA12CA4 | |
| SCHEMBL31153234 | 0.76 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL8336716 | 0.76 | CA2 (0.62) | CA2CA1CA9CA12CA4 | |
| SCHEMBL28102126 | 0.75 | CA2 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL28107398 | 0.75 | SOS1 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL29178993 | 0.75 | CA2 (0.96) | CA2CA1CA9CA12CA4 | |
| SCHEMBL202948 | 0.74 | CA2 (0.81) | CA2CA1CA9CA12CA4 | |
| SCHEMBL9097720 | 0.73 | CA1 (0.54) | CA2CA1CA9CA12CA4 | |
| SCHEMBL202328 | 0.73 | TGM2 (0.70) | CA2CA1CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| CN-1831144-A | Granulated sugar and production method thereof | NUERLAN KENJIAHAMAITI (CN) | 2006-09-13 | — | — | CN | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-9795603-B2 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160303133-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2983657-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | Numedii, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| CN-105263482-A | Treatment of gastrointestinal and other disorders | NUMEDII INC | 2016-01-20 | — | — | CN | disclosed |
| CN-105218632-A | As peptide or plan peptide, the Preparation Method And The Use of transglutaminase inhibitor | ZEDIRA GMBH | 2016-01-06 | — | — | CN | disclosed |
| WO-2014165823-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| US-6326364-B1 | BACTERICIDES | CEDARS-SINAI MEDICAL CENTER | 2001-12-04 | — | — | US | disclosed |
| CN-1285823-A | Phenyl-alkyl-imidazoles as H3 receptor antagonists | SCHERING CORP (US) | 2001-02-28 | — | — | CN | disclosed |
| WO-2000045803-A2 | USE OF 5-AMINOSALICYLATES AS ANTIMICROBIAL AGENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2000-08-10 | — | — | WO | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303133-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | ADRB1, ADRB2, ADRA2B | CA2 3595/4885CA1 4593/4885CA9 3490/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CA2 1000/4885CA1 1403/4885CA9 1018/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CA2 1023/4885CA1 1105/4885CA9 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.